Results 61 to 70 of about 13,099 (221)

Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]

, 2010
Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.
Jørgensen, Heather G., Jorgensen, Heather G., Tessa L. Holyoake, Heather G. Jørgensen, Scobie, Linda; id_orcid, Elliott, Moira A., Scobie, Linda, Crossan, Claire, Hatziieremia, Sophia, Zhou, Peixun; id_orcid, Elliott, Moira A, Sophia Hatziieremia, Michie, Alison M, Holyoake, Tessa L., Holyoake, Tessa L, Jørgensen, Heather G, Alison M. Michie, Halbert, Gavin W., Linda Scobie, Gavin W. Halbert, Moira A. Elliott, Claire Crossan, Michie, Alison M., Peixun Zhou, Halbert, Gavin W, Zhou, Peixun   +25 more
core   +1 more source

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Hatziieremia, S., Mountford, J.C.   +4 more
core   +1 more source

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters [PDF]

, 2009
Imatinib mesylate and nilotinib are highly effective at eradicating the majority of chronic myeloid leukemia (CML) cells; however, neither agent induces apoptosis of primitive CML CD34⁺ cells.
Holyoake, T.L., Davies, A., Jordanides, N.E., Giannoudis, A., Jorgensen, H.G., Harris, R.J., Hatziieremia, S., Mountford, J.C., Pirmohamed, M., Clark, R.E., Lucas, C.M.   +10 more
core   +1 more source

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks [PDF]

, 2011
The resistance of leukemic stem cells in response to targeted therapies such as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of multiple signaling pathways and molecules, including TGFβ, AKT, and FOXO transcription factors ...
Holyoake, T.L., Tessa L. Holyoake, Pellicano, F., Francesca Pellicano   +3 more
core   +1 more source

Targeting the oligomerization of BCR/ABL by membrane permeable competitive peptides inhibits the proliferation of Philadelphia Chromosome positive leukemic cells

, 2013
The BCR/ABL fusion protein is the hallmark of Philadelphia Chromosome positive (Ph+) leukemia. The constitutive activation of the ABL-kinase in BCR/ABL cells induces the leukemic phenotype.
Mahajna, Jamal, Schüll, Marion, Najajreh, Yousef, Ruthardt, Martin, Oancea, Claudia, Goldblum, Amiram, Beißert, Tim, Ottmann, Oliver G., Mian, Afsar Ali   +8 more
core   +1 more source

Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment

, 2009
Background: t(9;22) is a balanced translocation, and the chromosome 22 breakpoints (Philadelphia chromosome – Ph+) determine formation of different fusion genes that are associated with either Ph+ acute lymphatic leukemia (Ph+ ALL) or chronic myeloid ...
Xiaomin Zheng, Malcolm A S Moore, Martin Ruthardt, Ruthardt, Martin, Oancea, Claudia, Claudia Oancea, Malcolm A. S. Moore, Reinhard Henschler, Henschler, Reinhard, Moore, Malcolm A. S., Zheng, Xiaomin   +10 more
core   +1 more source

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells [PDF]

, 2011
Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease ...
E K Allan, Holyoake, T.L., Jorgensen, H.G., A R Craig, T L Holyoake, Allan, E.K., Craig, A.R., H G Jørgensen   +7 more
core   +1 more source

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines

, 2009
Background Imatinib mesylate, a selective inhibitor of Abl tyrosine kinase, is efficacious in treating chronic myeloid leukaemia (CML) and Ph+ acute lymphoblastic leukaemia (ALL).
Schwarz, Kerstin, Ruthardt, Martin, Romanski Annette, Romanski, Annette, Ruthardt Martin, Ottmann, Oliver G., Ottmann, Oliver G, Bacic, Biserka, Gwanmesia Patricia, Gwanmesia, Patricia Mambou, Schwarz Kerstin, Ottmann Oliver G, Bacic Biserka   +12 more
core   +1 more source

Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients [PDF]

Blood, 1993
Abstract We report here the results of polymerase chain reaction (PCR) for bcr- abl transcript and clinical details derived from 64 chronic myelogenous leukemia (CML) patients after allogeneic bone marrow transplantation (BMT). A total of 139 samples (2 to 220 weeks after BMT) were analyzed and bcr-abl transcript was detected in 99 ...
K, Miyamura, T, Tahara, M, Tanimoto, Y, Morishita, K, Kawashima, Y, Morishima, H, Saito, S, Tsuzuki, K, Takeyama, Y, Kodera   +9 more
openaire   +3 more sources

Clinical Applications of Phosphoproteomics: Illuminating Cancer Signaling and Enabling Rational Therapeutic Strategies

Cancer Science, Volume 117, Issue 4, Page 885-895, April 2026.
Mass spectrometry‐based phosphoproteomics for mechanistic dissection of cancer signaling pathways and uncovering therapeutic vulnerabilities. ABSTRACT Protein phosphorylation is a central post‐translational modification regulating cellular signaling, frequently dysregulated in cancer.
Hirokazu Shoji, Narikazu Boku, Jun Adachi   +2 more
wiley   +1 more source